Court rules against IMS, SDI on NH data ban

Share this article:
Supreme Court shrugs at NH data ban
Supreme Court shrugs at NH data ban
A federal appeals court has overturned a lower court's injunction of New Hampshire's ban on commercial provision of prescription data, arguing that such restrictions do not constitute an abridgment of free speech.

Writing for the US Court of Appeals for the First Circuit, Judge Bruce Selya said “we are not persuaded that the regulated data transfers embody restrictions on protected speech,” adding: “Unlike stereotypical commercial speech, new information is not filtered into the marketplace with the possibility of stimulating better informed consumer choice (after all, physicians already know their own prescribing histories) and the societal benefits flowing from the prohibited transactions pale in comparison to the negative externalities produced.”  

Two data companies, IMS Health and Verispan (now part of SDI), sued for an injunction against a New Hampshire law prohibiting the sale of prescribing data for use in pharmaceutical detailing, arguing that it violated their First Amendment rights. A US district court agreed with them. Today's decision overturns the district court injunction and opens the door to similar laws already on the books in Vermont and Maine and pending in two dozen more states.

In a joint statement, the data companies expressed disappointment with the decision and said they were evaluating potential next steps.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...